Brilliance ict

A radiological follow-up was performed to evaluate the radiological outcome of the treatment. The radiological follow-up consisted of a CT scan of the abdomen with i.v. contrast at 6 and 9 months after radioembolization. The follow-up CT scans were performed on a 256-slice CT (PHILIPS Brilliance ICT, Philips Medical Systems, Cleveland, OH, USA) and all images were reconstructed with a slice thickness of 2.5 mm.
All patients enrolled have been evaluated by a radiologist with more than 10 years of experience in abdominal CT scans. The radiological outcome was assessed using modified Response Evaluation Criteria in Solid Tumors (mRECIST) [14 (link)], which was evaluated 6 and 9 months after therapy.
The radiological follow-up was performed on 11 patients. Two patients treated did not join the follow-up for reasons unrelated to liver disease (Table 1).

All enrolled patients underwent CTU within 1–2 weeks prior surgery. Before the scan, patients were instructed to drink between 800 and 1000 ml of water, but not to urinate until the scan was over. After scanning, 50 mL of ioversol or 100 mL of iopamidol were intravenously administered, followed by 50 mL of saline at a rate of 3 mL/s. Images of the renal corticomedullary, nephrographic, and excretory phase were obtained at 25 s, 75 s, and 300 s after the thresholding of the thoracoabdominal aortic junction was reached. Subsequent analyses used only axial nephrographic phase images. Multidetector CT scanners with 64 to 128 detector rows (Siemens Healthineers, Philips Brilliance, and Philips Brilliance iCT) were used to obtain CT images. The scanning parameters were 120 kV, automatic mA settings (range 80–320 mA), layer spacing of 1 mm, and layer thickness of 1.5–3 mm. Soft tissue algorithm (window width (WW): 300–500 HU, window level (WL): 45–60 HU) were used after imaging.

Chest CT scans were performed with three multi-detector CT scanners (GE Optima 520 Pro, America; Philips Brilliance iCT, Netherlands; KAIPU CT precision 32, China). Each patient was scanned from the lung apex to the diaphragm during a breath-hold at end full inspiration and at end normal-expiration. CT acquisition was executed as follows: (a) GE Optima 520 Pro and Philips Brilliance iCT, tube voltage, 120 kVp; tube current, 250 mA; slice thickness, 1.25 mm; slice spacing, 1.25 mm; (b) KAIPU CT precision 32, tube voltage, 120 kVp; tube current, automatic mA; slice thickness, 1.25 mm; slice spacing, 0.7 mm. No contrast agent was administered.

All patients underwent CTPV with the absence of active bleeding for more than 48 hours after hospitalization. Before the examination, the patients fasted for 8–12 hours and practiced breathing exercises. Patients with tachycardia greater than 100 beats/min were given propranolol hydrochloride.
CTPV was performed using a 256-detector row CT scanner (Philips Brilliance iCT, Philips Healthcare, Best, The Netherlands) in three phases. Before the examination, 80 mL of iohexol (Omnipaque 350; Nycomed Amersham, Princeton, NJ) was administered intravenously as a contrast medium via a hand vein at 3.5 mL/s using a high-pressure injector. Images were obtained during the portal phase from the dome of the diaphragm to the iliac wing approximately 50–60 s after contrast injection, with the following parameters: section collimation, 0.625 mm; section thickness, 5 mm; pitch, 0.9; rotation time, 0.5 s per rotation; 120 kV; 343 mA. Three-dimensional CTPV images were reconstructed at an interval of 1.0 mm using the Philips EBW 4.5 workstation. Both maximum intensity projection and volume rendering were used for image reconstruction.